

Accelerate Diagnostics, Inc  
Form 8-K  
February 27, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported) **December 4, 2018**

**Accelerate Diagnostics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

001-31822                      84-1072256  
(Commission File Number) (IRS Employer Identification No.)

3950 South Country Club Road, Suite 470, Tucson, Arizona 85714  
(Address of principal executive offices)                      (Zip Code)

**(520) 365-3100**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As previously disclosed on a Current Report on Form 8-K filed by Accelerate Diagnostics, Inc. (the “Company”) on September 27, 2018, Joan Martin resigned from his position as Executive Vice President and Head of Europe, Middle East, and Africa of the Company.

In connection with Mr. Martin’s resignation, the Company and Mr. Martin entered into a certain Separation Agreement and General Release (the “Agreement”), dated December 4, 2018. Pursuant to the Agreement, the vesting of restricted stock unit (“RSU”) awards previously awarded to Mr. Martin in the amount of 16,100 RSUs was accelerated such that the RSUs fully vested as of Mr. Martin’s separation date.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which the Company will file as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2018.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCELERATE DIAGNOSTICS, INC.

(Registrant)

Date: February 26, 2019

/s/ Steve Reichling  
Steve Reichling  
Chief Financial Officer